ArticleScientific reports2026
Integrated analysis of single-cell and transcriptome data reveals temporal dynamics of microglial phagocytic reprogramming in neuropathic pain progression.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Neuropathic pain (NP) often progresses from acute to chronic, but the mechanisms driving this transition remain unclear. Microglia play a central role in spinal sensitization, yet their functional evolution during pain chronification is poorly understood. Through integrated multi-omics analysis and experimental validation, this study systematically investigates the temporal dynamics of microglial phagocytic reprogramming during the progression of neuropathic pain (NP). The results demonstrate that in the spared nerve injury (SNI) mouse model, spinal microglia undergo a dynamic evolution across three functional phases: an acute proliferative state with initial phagocytic activation (post-injury day 3, PID3), a transitional phase marked by significant activation of phagocytic pathways (PID7), and a chronic phagocytic "fatigue" state (PID14) in which autophagy- and lysosome-related pathway activity declined with a functional decoupling between phagocytosis and degradative capacity (PID14). Single-cell transcriptomic analysis further revealed functional heterogeneity among microglial subpopulations, including inflammation-regulating subsets (e.g., Micro3/Micro5) and specialized phagocytic clusters (e.g., Clusters 7). Pseudotime trajectory analysis indicated that microglia differentiate from a common progenitor state into two distinct fates: pro-inflammatory or phagocytic. Our analysis at the chronic phase (day 14 post-SNI) confirmed microglial activation, neuroinflammation, and pain hypersensitivity, alongside a novel finding of augmented microglial phagocytosis of apoptotic cells. Further research identified eight phagocytosis-related genes (such as Axl, Mfsd8, Mbtps1, and Sorl1), among which Axl showed the most significant up-regulation in the chronic phase. In vivo and in vitro experiments confirmed that inhibition of Axl not only induced mechanical allodynia but also impaired microglial phagocytic function. Furthermore, under LPS stimulation, microglial phagocytosis exhibited a biphasic response-initial enhancement followed by decline. This work provides new insights into microglial phagocytic reprogramming and suggests Axl as a promising therapeutic target for chronic neuropathic pain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.